Anti-alpha-enolase antibody as a serologic marker and its correlation with disease severity in intestinal behçet's disease

Sung Jae Shin, Byung Chang Kim, Tae Il Kim, Sang Kil Lee, Kwang Hoon Lee, Won Ho Kim

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Background: Intestinal Behçet's disease (BD) is a chronic inflammatory bowel disease, as are Crohn's disease (CD) and ulcerative colitis (UC). But unlike CD and UC, serologic markers for intestinal BD are not well known. Recently, anti-α-enolase antibody (AAEA) has been detected in sera from BD patients. Aims: The aim of this study was to evaluate the prevalence of AAEA in intestinal BD and its clinical correlations. Methods: The study sample included 80 patients with intestinal BD and 23 healthy controls. IgM AAEA was detected by ELISA. The positivity of IgM AAEA was defined as an optical density greater than three standard deviations above the mean of the control sera. Other parameters, such as demographic information, subtype of BD, colonoscopic findings, disease severity and treatment modality, were analyzed retrospectively. Results: The prevalence of IgM AAEA was 67.5% in intestinal BD and 0% in the control group. The positivity rate of IgM AAEA was higher in complete or incomplete BD than in suspected BD (77.5% vs. 51.6%, P = 0.016). The mean HBI score was higher in antibody positive patients than in antibody negative patients (5.60 vs. 4.61, P = 0.003). The cumulative probability of steroid use for aggravation of intestinal and extra-intestinal symptoms was higher in antibody positive patients than in antibody negative patients (P = 0.012). The number of patients with systemic involvement was higher in the AAEA positive group than in the negative group. Conclusions: Monitoring IgM AAEA may be helpful for diagnosis of intestinal BD and could be used to predict clinical course and disease severity.

Original languageEnglish
Pages (from-to)812-818
Number of pages7
JournalDigestive diseases and sciences
Volume56
Issue number3
DOIs
Publication statusPublished - 2011 Mar 1

Fingerprint

Intestinal Diseases
Phosphopyruvate Hydratase
Anti-Idiotypic Antibodies
Antibodies
Immunoglobulin M
Ulcerative Colitis
Crohn Disease
Serum
Inflammatory Bowel Diseases
Enzyme-Linked Immunosorbent Assay
Steroids
Demography
Control Groups

All Science Journal Classification (ASJC) codes

  • Physiology
  • Gastroenterology

Cite this

@article{70b6dc67f3f3465899c539dab17f6fec,
title = "Anti-alpha-enolase antibody as a serologic marker and its correlation with disease severity in intestinal beh{\cc}et's disease",
abstract = "Background: Intestinal Beh{\cc}et's disease (BD) is a chronic inflammatory bowel disease, as are Crohn's disease (CD) and ulcerative colitis (UC). But unlike CD and UC, serologic markers for intestinal BD are not well known. Recently, anti-α-enolase antibody (AAEA) has been detected in sera from BD patients. Aims: The aim of this study was to evaluate the prevalence of AAEA in intestinal BD and its clinical correlations. Methods: The study sample included 80 patients with intestinal BD and 23 healthy controls. IgM AAEA was detected by ELISA. The positivity of IgM AAEA was defined as an optical density greater than three standard deviations above the mean of the control sera. Other parameters, such as demographic information, subtype of BD, colonoscopic findings, disease severity and treatment modality, were analyzed retrospectively. Results: The prevalence of IgM AAEA was 67.5{\%} in intestinal BD and 0{\%} in the control group. The positivity rate of IgM AAEA was higher in complete or incomplete BD than in suspected BD (77.5{\%} vs. 51.6{\%}, P = 0.016). The mean HBI score was higher in antibody positive patients than in antibody negative patients (5.60 vs. 4.61, P = 0.003). The cumulative probability of steroid use for aggravation of intestinal and extra-intestinal symptoms was higher in antibody positive patients than in antibody negative patients (P = 0.012). The number of patients with systemic involvement was higher in the AAEA positive group than in the negative group. Conclusions: Monitoring IgM AAEA may be helpful for diagnosis of intestinal BD and could be used to predict clinical course and disease severity.",
author = "Shin, {Sung Jae} and Kim, {Byung Chang} and Kim, {Tae Il} and Lee, {Sang Kil} and Lee, {Kwang Hoon} and Kim, {Won Ho}",
year = "2011",
month = "3",
day = "1",
doi = "10.1007/s10620-010-1326-y",
language = "English",
volume = "56",
pages = "812--818",
journal = "American Journal of Digestive Diseases",
issn = "0002-9211",
publisher = "Springer New York",
number = "3",

}

Anti-alpha-enolase antibody as a serologic marker and its correlation with disease severity in intestinal behçet's disease. / Shin, Sung Jae; Kim, Byung Chang; Kim, Tae Il; Lee, Sang Kil; Lee, Kwang Hoon; Kim, Won Ho.

In: Digestive diseases and sciences, Vol. 56, No. 3, 01.03.2011, p. 812-818.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Anti-alpha-enolase antibody as a serologic marker and its correlation with disease severity in intestinal behçet's disease

AU - Shin, Sung Jae

AU - Kim, Byung Chang

AU - Kim, Tae Il

AU - Lee, Sang Kil

AU - Lee, Kwang Hoon

AU - Kim, Won Ho

PY - 2011/3/1

Y1 - 2011/3/1

N2 - Background: Intestinal Behçet's disease (BD) is a chronic inflammatory bowel disease, as are Crohn's disease (CD) and ulcerative colitis (UC). But unlike CD and UC, serologic markers for intestinal BD are not well known. Recently, anti-α-enolase antibody (AAEA) has been detected in sera from BD patients. Aims: The aim of this study was to evaluate the prevalence of AAEA in intestinal BD and its clinical correlations. Methods: The study sample included 80 patients with intestinal BD and 23 healthy controls. IgM AAEA was detected by ELISA. The positivity of IgM AAEA was defined as an optical density greater than three standard deviations above the mean of the control sera. Other parameters, such as demographic information, subtype of BD, colonoscopic findings, disease severity and treatment modality, were analyzed retrospectively. Results: The prevalence of IgM AAEA was 67.5% in intestinal BD and 0% in the control group. The positivity rate of IgM AAEA was higher in complete or incomplete BD than in suspected BD (77.5% vs. 51.6%, P = 0.016). The mean HBI score was higher in antibody positive patients than in antibody negative patients (5.60 vs. 4.61, P = 0.003). The cumulative probability of steroid use for aggravation of intestinal and extra-intestinal symptoms was higher in antibody positive patients than in antibody negative patients (P = 0.012). The number of patients with systemic involvement was higher in the AAEA positive group than in the negative group. Conclusions: Monitoring IgM AAEA may be helpful for diagnosis of intestinal BD and could be used to predict clinical course and disease severity.

AB - Background: Intestinal Behçet's disease (BD) is a chronic inflammatory bowel disease, as are Crohn's disease (CD) and ulcerative colitis (UC). But unlike CD and UC, serologic markers for intestinal BD are not well known. Recently, anti-α-enolase antibody (AAEA) has been detected in sera from BD patients. Aims: The aim of this study was to evaluate the prevalence of AAEA in intestinal BD and its clinical correlations. Methods: The study sample included 80 patients with intestinal BD and 23 healthy controls. IgM AAEA was detected by ELISA. The positivity of IgM AAEA was defined as an optical density greater than three standard deviations above the mean of the control sera. Other parameters, such as demographic information, subtype of BD, colonoscopic findings, disease severity and treatment modality, were analyzed retrospectively. Results: The prevalence of IgM AAEA was 67.5% in intestinal BD and 0% in the control group. The positivity rate of IgM AAEA was higher in complete or incomplete BD than in suspected BD (77.5% vs. 51.6%, P = 0.016). The mean HBI score was higher in antibody positive patients than in antibody negative patients (5.60 vs. 4.61, P = 0.003). The cumulative probability of steroid use for aggravation of intestinal and extra-intestinal symptoms was higher in antibody positive patients than in antibody negative patients (P = 0.012). The number of patients with systemic involvement was higher in the AAEA positive group than in the negative group. Conclusions: Monitoring IgM AAEA may be helpful for diagnosis of intestinal BD and could be used to predict clinical course and disease severity.

UR - http://www.scopus.com/inward/record.url?scp=79952443094&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952443094&partnerID=8YFLogxK

U2 - 10.1007/s10620-010-1326-y

DO - 10.1007/s10620-010-1326-y

M3 - Article

C2 - 20632102

AN - SCOPUS:79952443094

VL - 56

SP - 812

EP - 818

JO - American Journal of Digestive Diseases

JF - American Journal of Digestive Diseases

SN - 0002-9211

IS - 3

ER -